Schering Corporation

Merck Sharp + Dohme Corp.

John A Hey

Deen Tulshian

Ginny Dai Ho

Francis M Cuss

Lisa S Silverman

Julius J Matasi

Richard W Chapman

Ana Bercovici

Robbie L McLeod

Robert G Aslanian

Kevin D McCormick

Michael Berlin

Daniel M Solomon

Purakkattle J Biju

Yeon-Hee Lim

William Kreutner

Hongwu Yang

Yoon Joo Lee

Rema Danielle Bitar

John C Anthes

The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: 

C20-C21 substituted glucocorticoid receptor agonists

Novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein:

High affinity ligands for nociceptin receptor ORL-1

This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine Hreceptor antagonist/mmuscarinic antagonist, or a combination of a histamine Hreceptor antagonist and a mmuscarinic antagonist.

Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders

Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.

Treatment of upper airway allergic responses

Growing community of inventors

Nutley, NJ, United States of America

John A Hey